Is “CTGF” Still a Viable Anti-Fibrotic Target?

Abstract

Cellular communication network factor 2 (CCN2, formerly known as ‘connective tissue growth factor’ or ‘CTGF’) was the subject of anti-fibrotic drug development programs, largely in FibroGen, starting in the mid-1990s. This led to the development of FG-3019 (pamrevlumab) as a lead drug that was used initially to target diabetic nephropathy and subsequently pancreatic cancer, pulmonary fibrosis and Duchenne’s muscular dystrophy. All these programs failed clinically; diabetes in early development, and the others at Phase III. Could these failures have been anticipated? Is ‘CTGF’ dead as an anti-fibrotic target? What might have been done differently or could be done differently in the future? This personal commentary—based on years of experience first at FibroGen working on the ‘CTGF’ program and then as an independent academic researcher---aims to address at least some of these issues.

Ethics Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No novel data was generated or used in this study.

Funding

AL is funded by the Canadian Institutes of Health Research.

Declaration of Competing Interest

The author was a former employee of FibroGen. The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J. Cell Biol. 1991, 114, 1285-1294.

[2] Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell 1993, 4, 637-645.

[3] Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997, 8, 171-179.

[4] Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J. Investig. Dermatol. 1995, 105, 280-284.

[5] Shi-wen X, Pennington D, Holmes A, Leask A, Bradham D, Beauchamp JR, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp. Cell Res. 2000, 259, 213-224.

[6] Leask A. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J. Med. 2004, 53, 74-77.

[7] Shi-Wen X, Racanelli M, Ali A, Simon A, Quesnel K, Stratton RJ, et al. Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. J. Cell Commun. Signal 2021, 15, 71-80.

[8] Papavassiliou KA, Sofianidi AA, Spiliopoulos FG, Gogou VA, Gargalionis AN, Papavassiliou AG. YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis. Cells 2024, 13, 1519.

[9] Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 2002, 21, 473-482.

[10] Raghu G, Richeldi L, Fernández Pérez ER, De Salvo MC, Silva RS, Song JW, et al. ZEPHYRUS-1 Study Investigators. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial. JAMA 2024, 332, 380-389.

[11] Pamrevlumab Combo Does Not Improve Survival in Advanced Pancreatic Cancer. A available online: https://www.cancernetwork.com/view/pamrevlumab-combo-does-not-improve-survival-in-advanced-pancreatic-cancer (accessed on 14 August 2025).

[12] Leask A, Naik A, Stratton RJ. Back to the future: targeting the extracellular matrix to treat systemic sclerosis. Nat. Rev. Rheumatol. 2023, 19, 713-723.

[13] Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett. 1993, 327, 125-130.

[14] Perbal A, Perbal B. The CCN family of proteins: a 25th anniversary picture. J. Cell Commun. Signal 2016, 10, 177-190.

[15] Lau LF. Cell surface receptors for CCN proteins. J. Cell Commun. Signal 2016, 10, 121-127.

[16] Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J. Cell Physiol. 1999, 181, 153-159.

[17] Shi-wen X, Stanton LA, Kennedy L, Pala D, Chen Y, Howat SL, et al. CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J. Biol. Chem. 2006, 281, 10715-10726.

[18] Mori Y, Hinchcliff M, Wu M, Warner-Blankenship M, M Lyons K, Varga J. Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp. Cell Res. 2008, 314, 1094-1104.

[19] Liu S, Shi-wen X, Abraham DJ, Leask A. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum. 2011, 63, 239-246.

[20] Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenes. Tissue Repair. 2011, 4, 4.

[21] Makino K, Makino T, Stawski L, Lipson KE, Leask A, Trojanowska M. Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Res. Ther. 2017, 19, 134.

[22] Leask A. CCN2: a bona fide target for anti-fibrotic drug intervention. J. Cell Commun. Signal. 2011, 5, 131-133.

[23] Leask A. Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancers. Am. J. Physiol. Cell Physiol. 2020, 318, C1046-C1054.

[24] Ramazani Y, Knops N, Elmonem MA, Nguyen TQ, Arcolino FO, van den Heuvel L, et al. Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol. 2018, 68-69, 44-66.

[25] Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, Guzman D, et al. FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition. Pharm. Res. 2016, 33, 1833-1849.

[26] Neiens V, Hansbauer EM, Jaquin TJ, Peper-Gabriel JK, Mahavadi P, Snyder ME, et al. Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Nat. Commun. 2025, 16, 3251.

[27] Overcoming Failures: Lessons From IPF Clinical Trials in the Past Year. Available online: https://www.ajmc.com/view/overcoming-failures-lessons-from-ipf-clinical-trials-in-the-past-year (accessed on 15 September2025).

[28] Trachalaki A, Lindahl AL, Petrarulo S, Margaritopoulos GA. “Regression to the truth”: lessons learned from negative IPF trials. Breathe 2025, 21, 240260.

[29] Kurundkar AR, Kurundkar D, Rangarajan S, Locy ML, Zhou Y, Liu RM, et al. The matricellular protein CCN1 enhances TGF-β1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury. FASEB J. 2016, 30, 2135-2150.

[30] Fischer AG, Elliott EM, Brittian KR, Garrett L, Sadri G, Aebersold J, et al. Matricellular protein CCN1 promotes collagen alignment and scar integrity after myocardial infarction. Matrix Biol. 2024, 133, 14-32.

[31] Quesnel K, Shi-Wen X, Hutchenreuther J, Xiao Y, Liu S, Peidl A, et al. CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis. Matrix Biol. Plus. 2019, 3, 100009.

[32] Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J. Clin. Investig. 2009, 119, 772-787.

[33] Riser BL, Barnes JL, Varani J. Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J. Cell Commun. Signal 2015, 9, 327-339.

[34] Peidl A, Perbal B, Leask A. Yin/Yang expression of CCN family members: Transforming growth factor beta 1, via ALK5/FAK/MEK, induces CCN1 and CCN2, yet suppresses CCN3, expression in human dermal fibroblasts. PLoS ONE 2019, 14, e0218178.